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Objectives. The pur e of this study was to determine the 
immediate and long-term ungio~raphi~ and clinical results of 
coronary stenting. 
~ac&g~ou~d. Alt h ~re~im~oury trials of endovascular 
ed promising results, lack of long-term 
follow=up has limited the critical evaluation of the r&z of coronary 
stenting in the treatment of obstructive coronary artery disease. 
Meti&. A total of 250 procedures using the Palmax-Scbatz 
stent, performed in 220 patients between June 1988 and July 1991, 
were xamined. Minimal lumen diameter of the treated segments 
was measured on angiograms obtained before, after and 6 months 
after intervention. 
Results. Stent placement was successful in 246 (98%) of 250 
lesions, reducing di eter stenosis from 73% to -2.5%. There 
were no deaths or ave myocardial infarctions. CBne patient 
1 required emergency bypass surgery and one (0.4%) devel- 
oped subacute thrombosis. Femoral vascular complications oc- 
curred in 36 patients (16%). 
Six-month angio~rapbtc follow-up was obtained in 91% of 
Percutaneous transluminal coronary angioplasty currently 
provides approximately one half of all coronary revascular- 
izations in the U.S. (1). Despite improved success and safety 
(as documented in the second National Heart, Lung, and 
Blood Institute Registry of Coronary Angioplasty (2)), acute 
vessel closure and late restenosis remain significant prob- 
lems (3). In an effort to reduce the incidence of these 
problems, a variety of new devices, techniques andpharma- 
cotherapies have been delfeloped, including directional cor- 
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eligible patients. T 
r50%) was 25%. 
was signiiicantty higher for stents 
s the right coromary artery ( 
tic patients (56% vs. 20%; p = 
post-stent lumen diameter 4.31 
Stenting of the leh anterior desc 
predictor (p = 0.01) of restenosis m a mu 
survival was 97% and event-free survival 
myocardial infarction or revas~ularizatio~~ was %% &i 36 
months. 
Conclusions. ~almaz-Sc~tz stents can 
with a low inci 
reste~~s~s rate 
cardiova~olar even 
lumen diameter and stenting of the lefY anterior depending artery 
are associated with higher rates of restenosis. 
(J Am Coil C~dio~ 1992;20:~28-~~) 
onary atherectomy, thermal laser welding and laser ablation 
(1). 
The concept of an endovascular p osthesis was first 
proposed by Dotter (4) in 1969, but the first human coronary 
stent was placed by Sigwart et al. (5) nearly 20 years later. 
Subsequently, four different stent designs have been suc- 
cessfully imp!anted in the human coronary circulation: the 
self-expanding cndovascular Wallstent (Medinvent), and 
three balloon-expandable stents (Gianturco-Roubin [Cook], 
Palmaz-Schatz [Johnson & Johnson Interventional Systems] 
and Wiktor [Medtronic] stents (5-8)). Although each of 
these devices has shown promise in early trials, the rela- 
tively small number of patients treated and lack of long-term 
follow-up have made critical evaluation oftheir performance 
difficult. Serruys et al. (9) reported on the immediate out- 
come and 6-month follow-up in the first 105 patients treated 
with the Wallstent stent and showed a high (24%) incidence 
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All patients had objective vidence of myocardiat isch- 
emia by either exercise treadmill testing or spontaneous 
ischemia t rest. Advanced 
heart failure, previous 
nary revascularization 
tients with a contraindication to aggressive anticoagulant 
therapy were excluded. 
Stents were placed in vessels with a reference diameter 
b2.75 nm and diameter stenosis ~70%. During the initial 
phase of the study (the first 37 procedures), only native vi 
coronary arteries were stented (11). Thereafter, animprov 
sheathed elivery system 
arteries, as well as in saphenous 
vein bypass grafts. Although eight patients received over- 
lapping tandem stems during the initial phase of the study, 
subsequently only lesions that could be covered by a single 
(15 mm long) stent were treated because of a recognized high 
(>50%) rate of restenosis ntandem stent placement (11). 
Stint ~~ace~e~~. The procedure for placing the rigid and 
articulated stent in the first 40 patients has been described 
previously (12). The stent was crimped onto a standard 
angioplasty halloon and delivered through a 9F guiding 
catheter over a 0.014 in. (0.834 cm) guide wire (High Torque 
Floppy, Advanced Cardiovascular Systems). Subsequent 
stems, however, were placed with use of one of two sheath 
systems. In 104 procedures, the stem-ballcon assembly was 
advanced across the lesion through a 5F superselective 
guiding sheath (Teleguide, Schneider) that had been posi- 
tioned distal to the stenosis by advancement over a conven- 
tional balloon used for predilation. The guiding sheath was 
orning. A11 patients receive 
300 s. All patients co~ti~oed to receive 
but in all subsequent patients warfarin, ti 
thrombin time of 16 to 18 s, was given for 8 weeks after stem 
placement. Antibiotic pro hylaxis against bacterial en- 
urmg the study period vas- 
cular sheath removal w managed with three 
procedure and discontinued 4 h before sheath removal the 
next morning. In the next 69 procedures (Group II), no 
additional heparin was administered after the procedure, and 
the vascular sheath was removed 4h later. In the ng 
120 procedures (Group III), the sheath was remo bm 
day of the procedure as soon as the activated clotting timi 
decreased to180 s. In all three strategies intravenous herald 
was restarted without a bolus dose 2 h after sheath removal. 
A major vascular complication was defined as any vascular 
event (such as ps~udoa~eurysm, arteriove~o~s fistula) re- 
sulting in either transfusion or surgical repair. 
Ali patients were contacted 
ks; at 2, 4, and 6 months, an 
assess clinical events (death, myocardia] in
revascularization procedure [bypass urgery or coronary 
angioplasty]). These events included any myocardial i 
tion, angioplasty or surgical revascular~zatio~ assoC 
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Table 1. Baseline Demographics in 220 Patients -.-- __v- 
Characteristic -- - 
Age (yr) (mean 2 SD; range) 
Male gender 
Smoking 
:-ly~l‘tellSi~r. 
Diabetes me!!itus 
Family history of CAD 
Serum cholesterol 
>iiM mgldl 
Mean 2 S3; range 
HDL fraction 
Remote MI P6 months) 
Recent Ml (<6 months) 
Unsrable angina 
Multivessel CAD 
Previous CABC 
No. 
--_ _-_- 
60 + 12; 35 to 85 
180; 82% 
110; 50% 
108; 49% 
37; 17% 
119; 54% 
128; 58% 
200 + 37; 102 to 314 
38 2 IO: 18 to 77 
92 (42) 
40 (18) 
1.54 (70) 
II4 (521 
67 (30) 
CABS = coronary artery bypass grafting; CAD = coronury artery 
discasc; HDL = high density lipoprotein; MI = myocardial infarction. 
with the stented or any other vessel. Eight patients were lost 
to follow-up. Follow-up coronary angiography was per- 
formed between 4 and 8 months after stenting unless earlier 
angiography was clinically indicated; 91% of all eligible 
patients underwent such angiographic follow-up. 
Anglographic analysis. As previously described (1 I), 
each stented lesion was measured from an optica!!y magni- 
fied image in a single, matched “worst view,” compared 
with the 9F (3.0.mm) guiding catheter as a reference object, 
using digital calipers (Fowler Ultra-Cal II). Measurements 
included minimal lumen diameter before conventional coro- 
nary angioplasty and after stent placement. The diameter of
the proximal nd distal reference segments was averaged to
a give a mean reference diameter. 
In the follow-up angiograms, in-stem stenosis was calcu- 
lated from the minimal umen diameter within the stem 
compared with the mean reference segment diameter. Re- 
stenosis was defined as a stenosis 250% within or immedi- 
ately adjacent to he stent. 
StaWcal analysis. Data were expressed as the mean 
value * SD of the mean. The association of restenosis 
(defined as ~50% reduction in lumen diameter) with cate- 
goric and continuous variables was performed by using 
cm-square and logistic regression, respectively. Univariable 
analysis demonstrated three variables sufficiently significant 
(P < 0.05) for entry into a step-up multivariable model. 
Event-free survival after stent placement was determined by
Kaplan-Meier techniques and displayed as a standard sur- 
vival curve. 
Gent characteristics. Between June 1988 and July 1991, 
placement of 250 Palmaz-Schatz coronary stents was at- 
tempted in 220 patients (Table 1). The patients had a mean 
age of 60 years and 82% were men. The majority ofpatients 
‘1 
i 
enth/Vear 
RCA 
94 (38%) 
Figure I. A, Total number and vessel distribution of stents piaced 
during each Gmonth interval throughout the study period. 
B, Distribution f stenl placement byvessel. CX and LCX - left 
circumflex coronary artery; LAD = left anterior descending coro- 
nary artery: LM = left main coronary artery: RCA = right coronary 
artery; SVG = saphenous vein graft. 
had either a recent myocardial infarction or unstable angina. 
Lesions were selected for stenting if there was a higher 
presumptive likelihood of either immediate closure (as in 
eccentric lesions) or restenosis (as in vein graft or previously 
dilated lesions) with conventional coronary angioplasty. 
Although 8 of the initial 28 patients had overlapping tandem 
stems placed, thereafter tandem stenting was avoided. How- 
ever, seven patients had two noncontiguous stunts placed in 
a single vessel and six patients had a single stent placed in 
two different vessels during the same procedure. In the first 
18 months of the study stenting constituted only 4% of 1,015 
coronary interventions, but in the last 16 months the propor- 
tion increased to 17% of the 1,131 coronary interventions 
performed in our institution (Fig. IA). 
aseline angiography. Although the first 37 patients had 
stents placed exclusively in the right coronary artery, 77 
stents were subsequently placed successively in the left 
anterior descending, left circumflex or left main coronary 
artery (Table 2). Thus, although the majority of native 
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No. % 
m 
Vessel (n = 250 lesions) 
Native 1 
53 21 
94 38 
23 9 
LM I <I 
SVG 84 34 
Prior treatment 
Native vessel 
Initial treatment 58 35 
Prior RTCA 108 65 
SW 
lnitiaf treatment 6*? 72 
24 28 
hforpholo8y 
T0tal occlusion 17 7 
Eccentric morphology 83 33 
Calcification 9 3.5 
ior descending coronary artery; = left circumtlex 
= left main coronary artery; = percutaneous 
transluminal coronary angioplasty; RCA = right coronary artery; SW = 
saphenous vein graft. 
coronary stents were placed in the rig 
(56%), a significant number were al 
amerl5r descending (31%) or circu 
in saphenous vein grafts. 
(52%) had previously be 
nary amgiQ~~asty; the 
lesions (no previous treatment 
diameter (Table 3) was 3.4 -1- 
with a mean pretreatment s ameter of 0.77 15 
0.15 mm (range 0to 2.68), corr 
stenosis of 71%. The mean length of lesions treated with a 
single stent was 7.16 2 4.12 mm. Seventeen stents (7%) were 
c ozza ET AL. 331 
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Table 3. Quantitative Angiography Before and After Steuting in 250 Lesions 
. P 
Baseline After Stenting 
Reference artery diameter (mm) 
All vessels 3.40 2 0.62 (1.85 to 5.5) 
Native 3.24 + 0.58 (2.85 to 5.2) 
LAD 3.06 f 0.46 (1.85 to4.59) 
RCA 3.43* + 0.64 (1.95 to 5.2) 
SVG 3.62 f 0.68 (2.37 to5.5) 
Lumen diameter (mm) 
All vessels 0.77 t 0.54 (0 to 3.12) 3.42 + 0.61 (1.95 to 5.2) 
Native (all) 0.71 2 0.48 (0 to 2.34) 3.34 k 0.54 (I.80 to 5.27) 
SVG 0.90 + 0.64 (0 to 3.12) 3.57 k 8.61 i2.01 to 5.04) 
Diameter stenosis (%) 
All vessels 172 15 -2.5 f 13 
Native vessels 78+ 14 -3.3 k 13 
SW 75 ?I I7 -1.0 + 14 
*p = 0.003 (compared with LAD). Values in parentheses indicate range of ValUeS; ah other values are mean 
values + SD. Abbreviations a in Table 2. 
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Figure 2. Angiograms of a saphenous 
vein graft. Left, at baseline. ~~~t~~~ 
After conventional balloon angio- 
plasty, the lumen is enlarged but sig- 
nificant stenosis and plaque disruption 
i&t, After stent place 
1 stenosis is present an 
resulting lumen is smooth. 
stent placement in the setting of erroneous discontinuation 
of watfarin therapy. There wire no deaths or Q wave 
myocardial infarctions. Ten non-Q wave myocardial infarc- 
tions (4%) occurred uring the procedure; seven of these 
followed stenting of a saphenous vein graft, presumably asa 
result of distal embolization. 
Successful stenring resulted inan increase in mean lumen 
diameter f om 0.77 to 3.42 mm (p < 0.05) with a residual 
stenosis of -2.5 f 13% (Table 3, Fig. 2). The final balloon 
size/reference artery ratio was I. 1 + 0.16. 
Complications. Overall, vascular complications occurred 
in 36 patients (16%) and were the most frequent adverse 
events associated .wiih ihe procedure, They uccur-red in 8 
patients (25%) in Group 1 and in 13 patients (19%) in Group 
II. In the last 120 patients (Group III) sheath removal 
performed on the same day as tent placement $5 soon as 
the activated clotting time decreased to 180 s) resulted in I5 
vascular complications ( 13%). Specific vascular complica- 
tions included 12 pseudoaneurysms (5%). 6 arteriovenous 
fistulas (3%) and 6 retroperitoneal hemorrhages (3%). 
Twelve patients (5%) required transfusion for hemorrhagic 
complications and 24 (1 I o/o) required surgical repair. 
iographic follow-up, Six-month angiographic follow- 
up was obtained in I17 patients treated with a single stent. 
Although this represents ~50% of the total study population, 
it accounts for 91% of 129 patients eligible for follow-up (that 
is, patients >4 months after stent placement) at he present 
time. The eight early patients who received a tandem stent 
have been descr,bed previously (11) and are excluded from 
the current analysis of restenosis in single stents. However, 
patients who received more than one noncontiguous stent in 
a vessel are included in the analysis. 
Restenosis rate. The mean time to follow-up angiography 
was I75 + 51 days. Table 4 shows an overall angiographic 
restenosis rate for single nontandem stents ubgrouped into 
native vessel versus vein grafts and primary versus re- 
stenotic lesions after prior interventton. A trend toward a 
lower ate of restenosis was found for primary lesions than 
for restenotic lesions ( I% vs. 28%; p = NS). Stenting ofthe 
left anterior descending versus the right coronary artery was 
associated with a s~gn~~c~ntIy higher ate of restenosis (44% 
vs. 12%, relative risk = 3.67, p = 0.002) 3A). Another 
predictor f angiographic restenosis in ste lesions (Table 
ellitus (56% vs. 20%; relative risk 
= 2.80, p = 0.006). 
Finally, stented vessels whose lumen diameter postpro- 
cedure was below the median (C3.31 mm 
significantly higher incidence of restenosis tha 
the median (34% vs. 16%; relative risk = 2. 
(Fig. 3). The mean reference artery diameter was signifi- 
cantly smaller for the left anterior descending than for the 
right coronary artery (3.06 + 0.46 vs. 3.43 + 0.64 mm, p = 
0.003), but multivariabl analysis revealed that stenting of 
the left anterior desce ing artery remained the strongest 
indepecdezt predictor of restenosis (p = 0.01) (Table 5). 
Age, gender, serum cholesterol, smoking, hypertension, 
recent myocardial infarction, unstable angina, lesion length 
or halloon size were not determinants of reztenosis n this 
analysis. 
Long-term follow-up. Clinical follow-up was available for 
212 (98%) of 220 patients. Figure 4 shows early and long- 
term freedom from cardiovascular events (death; myocar- 
dial infarction or repeat revascularization) as assessed by 
Kaplan-Meier analysis. The event-free survival rate was 
88% at 6 months and 70% at 36 months. Five patients died 
during the follow-up period. One patient died of adult 
respiratory distress yndrome and bronchopneumonia 2 
months after stent placement. Postmortem examination doc- 
umented a widely patent stent. A second patient died 2.5 
Table 4. Restenosis Rates (~50% Diameter Stenosis) by Vessel 
and Previous Treatment 
All Lesions Prisnary Lesions Prior PTCA 
All stents 29/I 17; 25% 8142; 19% 21175; 28% 
Native vessels 21185; 25% 4124; 17% 17161; 28% 
LAD 12127; 44% 216; 33% :>/21; 48% 
RCA 6148; 12%* 1116; % 5132; 16% 
SVGS 8132; 5% 4118; 22% 4114; 28% 
*p = O.OQ2 (versus LAD). Abbreviations a  in Table 2. 
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post-stent lumen diameter 4.31 mm and fix diabetic patients. 
100 
=Q.O02 
I 
80 
-20 
00 
le 5. Predictors of Restenosis 
_I-- 
Univariable 
Relative 
Risk 
- 
p V&e 
Demographic 
Age 
Gender 
Nyperknsion 
Diabetes meilitus 
Serum cholesterol >2Ml mg/W ml 
Family history of CAD 
Cigaretle smoking 
An~i~gra~~jc 
Native vessel vs. SVG 
hitid treatment vs. prior PTCA 
LAD (vs. RCA) 
Post-slenr lumen c3.3 mm 
Illultivuriable 
LAD (versus RCA) 
- NS 
- NS 
- NS 
2.80 0.0% 
- NS 
- NS 
- NS 
i’ost-stent lumen c3.3 mm - Q.II 
Diabetes mellitus - 0.10 
Abbreviations as in Table 2. 
acement of a St31 in the rig 
xa~~~atiQ~ do~~~e~ted a large, acute anterior 
iial infarction with a patent right coronary 
artery stem. in two patients cardiac arrest was d~e~cd to be 
ause of death, but no postmorten. ~~~~~~at~o~ was 
med. The cadse of dea not dt te~~ine~ in the 
fifth patkr?~ Three oc~~~~~~ted ~yoca~d~a~ 
infarction during the follow,, ut the infarct terri- 
tory was supplied by the ste n only one patient. 
Eight patient,s (3.7%) required coronary bypass surgery and 
19 (9%) underwent coronary a~gio~lasty of either the stcnted 
(n = IS) or a nonstented (n = I) vessel. 
Figure 4. Freedom from death, myocardial inkctinn ( 
cardiac events (death, myocardiai infarction or repeat revascular- 
ization). Such events include those precipitated by other vessels in 
patients with proved stem patency bee text). The incidence ofdeath 
or myocardial infarction approximates that of death alone because 
two of three patients who had an infarction also died. 
0-l 
d 
I I 
6 1: iI3 24 30 36 
MONTHS POST-STENT 
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Fourteen years after Gruentzig and colleagues (13) re-
ported performance of the first percutaneous transhImina1 
coronary angioplasty procedure, technologic advances (1) 
and greater operator experience (14) have resulted in a 
significant improvement in immediate procedural success 
from 6j$$ to 85% (2). Nevertheless, abrupt vessel closure 
continues tonecessitate emergency b pass urgery in 2% to 
4% (15,16) and restenosis continues to occur in 35% (17) Of 
coronary angioplasty procedures. It has been suggested that 
stenting of coronary arteries may favorably affect both of 
these processes. 
Immediate results. After ‘the ncouraging results in early 
animal studies (6,18), Sigwart et al. (5) implanted IO self- 
expanding Medinvent stents in human peripheral rteries in 
1987. Medinvcnt s ents were then implanted inhuman ative 
coronary arteries and saphenous vein grafts after conven- 
tional coronary angioplasty. Although the initial results were 
favorable (5), a larger early trial (9) of the Medinvent s ent 
revealed an unacceptably high incidence rate (24%) of in- 
stent hromboses occurring within the first several weeks 
despite an aggressive anticoagulant regimen. 
In a much smaller series, Garratt et al. (19) reported a
94% success rate for delivery of the balloon-expandable 
Gianturco-Roubin stent placed electively or for threatened 
vessci c!tisbie. Sir&l:~, Z&&in et al. (6) reported success- 
ful placement of 14 (88%) of 16 Gianturco-Roubin stents as a 
bridge to bypass surgery. 
In the U.S. the largest experience to date of coronary 
stenting has been with the Palmaz-Schatz balloon- 
expandable stent. As of July 1991, > 1,200 stents have been 
placed in I..100 patients ince 1987 (Johnson & Johnson 
lnterventio;kll Systems, personal communication, 1991). 
The origkral rigid design (developed by Palmaz [20]) was 
deployed successfully in24 (80%) of 30 lesions (7). Schatz 
(12) subsequently modified this prototype to include a cen- 
tral articulation that facilitates passage through standard 
guiding catheters. Stents with the articulated design were 
Successfully delivered without a protective sheath in 275 
(9S%) of 291 attempts (7). Determinants of successful deliv- 
ery included increased operator experience st ting of the 
right coronary artery, proximal versus distal ocation and 
absence ofdissection. 
Results of our initial cohort of 35 patients receiving the 
Palmaz-Schatz s ent demonstrated a 95% successful p ace- 
ment rate in the right coronary artery (12). Our present s udy 
confirm that stents can also be deployed in the left coronary 
artery branches and in saphenous vein grafts with a compa- 
rably high success rate with a sheathed delivery system. This 
high success rate and low (0.4%) incidence rate of acute 
closure requiring emergency b pass urgery compare favor- 
ably with rates reported for conventional coronary angio- 
PlastY (1,2,15,16). In fact, several centers (19,21,22) have 
documented the ability of stents to successfully reverse 
abrupt closure occurring in the setting of elastic recoil, focal 
dissection and comnary V~SOS 
properties may have been us 
sure of the stented artery. 
Subacute th ask. Local thrombus for.~atio~, 
ever, remains blem with all stems. Schatz et al. (25) 
showed that the struts of stents placed in canine coronary 
arteries were covered with thrombus wi n I week. Forma- 
tion of a more extensive (occ?usive) thrombus within the 
stent can occur at any time within the first several weeks 
after implantation before This devastat- 
ing complication f subacute t 
ia total vessel occlusion, my 
~nadeq~l~~te a~t~coa~~~~~t ther is the kpkost irn~~~a~t 
factor predisposing to subacut 
In the initial rn~~tice~t~~ re edinvent stent 
(9), the highest thrombosis rate (39%) occurred in p 
treated with subcutaneous he~~~~~ rather than w 
Schatz (12) has subsequently shown that the additio 
molecular weight dextran (to a rt:gimen of aspirin, dipyrida- 
mole and Ilebirin) decreases tQe thrombogenicity of the 
Pahnaz stent placed in dogs, but dextran was not given 
initially to patients in the European trial of the 
stent. The inclusion of both dextran and warfa 
part, account for a lower incidence ofsubacute ciosure in the 
current study compared with the 24% inci 
with the Medinvent stent. Despite the a 
dextran and warfarin to the anticoagulant IT 
quent patients, the rate of subacute closu 
vent stent has remained >lO%. This finding suggests hat 
inherent properties ofthe Medinvent s ent, such as its high 
metal content and overlap~~~g se ments, may be intrinsi- 
cally more thrombogenic. 
Another contribution to the low rate of subacute closure 
in our series is that we did not use the stent o treat acute 
closure, an indication that may be associated with a higher 
incidence ofsubacute closure (6). Finally, inadvertent inter- 
ruption of anticoagulant therapy shortly after stent implan- 
tation is known to predispose to stent hrombosis. In our 
series the only instance of subacute thrombosis occurred 
after mistaken discontinuation f warfarin within 1 week of 
the procedure. We therefore chose to continue full antico- 
agulant herapy even in the setting of ongoing vascular 
bleeding. Although this treatment may have resulted in a 
higher incidence ofvascular complications than that ofother 
centers, it appears from our later experience that the inci- 
dence of such complications can be reduced somew&t by 
judicious management of anticoagulation a d timing of 
sheath removal, without an increase in stent thromboses. 
Although at the present time our vascular complication rate 
is less than half that observed in the initial cohort (Group I 
patients), the present rate of 13% is significantly higher than 
that seen with conventional coronary angioplasty. 
&stenosis. Neither improvement in angioplasty equip- 
ment nor concomitant pharmacotherapy hasbeen shown to 
reduce the incidence ofrestenosis after coronary angioplasty 
(26). Although the reported (26) incidence of restenosis 
ticenter experience wtt 
larly shows a low (20%) overall a~giographic i~~cid~~ce of 
restenosis. 
uded 250 stems with 
inical(96%) f~l~~w-~ 
nary ste~t~~g report 
erience. Because 
lesions treated in our series one or more pre~~acement 
characteristics predictive of an increased incidence of sub- 
sequent restenosis (32- 35), these data suggest that stenting 
may have a favorable impact on restenosis. The high proce- 
dural success rate, the absence of subacute closure in 
patients adhering to the prescribed anticoagulant regimen 
and the lower than expected restenosis rate suggest that 
coronary stenting may beparticularly valuable for treating 
lesions in saphenous vein grafts for which a recent series (36) 
found a restenosis rate of >60% with conventional coronary 
angioplasty. 
Oar data also indicate that the observed rate ofresteno- 
sis after stent placement depends on varims patient arzd 
/esian c/ztiruacrksricJ. Diabetes has been associated with a 
higher incidence of restenosis after conventional balloon 
angioplasty (28) and emerges a  a strong predictor of reste- 
nosis after stenting. The absence in our study of a difference 
between diabetic and nondiabetic patients in vessel size 
(mean reference artery diameter 3.36 -t 0.64 vs. 3.39 + 
0.65 mm; p = NS) suggests hat vessels in diabetic patients 
may have an underlying predisposition to greater local 
intimal hyperplasia. Stenting of the right coronary artery 
also appeared to be associated with a lower incidence of 
restenosis than that observed with stenting of the left ante- 
rior descending coronary artery. This finding agrees with 
data from the M-HEART study (31) documenting a lower 
incidence of restenosis f r the right coronary versus the l ft 
anterior descending artery after conventional balloon angio- 
plasty. Using multivariable analysis, Muntz et a!. (37) found 
that he lower estenosis rates een for right coronal yartery 
lesions treated with either a stent or directional coronary 
atherectomy may be explained by both a larger reference 
vessel diameter and less subsequent late loss (that is, the 
re and fobow-up) in
anterioa- dessendlng 
which is a complex biofogic process involvm~ a
s? Renslng et al. (38) found that u:, SQ 
50% of the gain achieved during successfu8a8 balloon an 
ult of elastic recoil. 
tb~oretica~~y preserves 
mediate gain usually iast to elastic recoil or 
is rcccii makes residual stenoses of 20% to 
e vessel c osure (43). 
gain and to leave ess~~t~a~~y no residual slmxis. 
§t~~t~~~ than after 
rtance of this large 
ported by our data showing si ly lower restenosis 
rates when the post-stent lumen r exceeds 3.31 mm, 
a preliminary finding previously note y analysis of a small 
stenting compared with other core ~~terve~~~o~s is due 
nor to a decrease in intimal hyp sia, but to a larger 
lost-treatment lumen diameter. 
rest&s. Finally, although the long-term (5 to 
cts of stenting have t to be established, our
data show that ~2% of patients di
any significant cardiac events (death, myocardia~ infarction 
or repeat revascularization) in the 1st 6 months after stem 
placement despite apatient cohort with a high incidence of 
prior infarction (60%), multivessel coronary artery disease 
(XI%), prior bypass urgery (30%) and angiographic features 
associated with increased rates of restenosis (97%). Even 
including events occurring inpatients with document 
patency at 6 months, there appeared to be only 
further decrease in event-free survive? tj 36 months, sug 
gesting that clinically signifirs.ar events (including resteno- 
sis) are uncommon after 6 mont s. This observation is
consistent with dat (43) showing t at progression f reste- 
nosis in stems is uncommon aft months and it provides 
reassurance that the salutary cts of stenting wiii be 
maintained over time. 
Li s. This study has several important limitations. 
The I oon angioplasty control grou 
in QW series precludes any ect comparison f stenting an 
angioplasty, and i irect comparisons are hampered by a 
selection bias excluding patients with small or diffusely 
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diseased vessels from stenting. Any cost-benefit analysis 
should also consider the fact that a patient with a stent 
requires a longer hospital stay during initiation of warfarin 
therapy. The higher incidence of local vascular complica- 
tions would further prolong the hospital stay and increase 
costs. The STRESS @tents in Restenosis Study) trial, a 
multicenter randomized trial comparing conventional angio- 
plasty and Palmaz-Schatz stenting will provide a direct 
comparison f the safety and efficacy of these approaches. 
Another limitation of this study isthe use of digital calipers 
rather than a computerized quantitative ngiographic sys- 
tem, Although this technique might be expected todecrease 
the accuracy of measurement, the effect isdistributed toall 
groups and therefore should not introduce bias into the 
study. Lastly, although our series contains 220 patients, it
still lacks suficient [ Jwer to exclude a type II error when 
comparing small subgroups ( uch as comparisons between 
primary versus restenotic lesions). 
Conclusions. Despite these limitations, this series dem- 
onstrates that stents can be placed with a high rate of success 
in both native coronary arteries and vein grafts. Further- 
ts the ability of aggressive anticoagulant 
therapy to largely eliminate major complications such as 
subacute closure although such therapy may increase the 
risk of vascular complications. In a group of patients at high 
risk for restenosis, stenting was associated with a lower than 
expected rate of restenosis, especially for the right coronary 
artery and saphenous vein graft lesions, 
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